Schmidt, C., Lepsverdize, E., Chi, S.L., Das, A.M., Pizzo, S.V., Dityatev, A. and Schachner, M. (2008) Amyloid Precursor Protein and Amyloid Beta-Peptide Bind to ATP Synthase and Regulate Its Activity at the Surface of Neural Cells. Molecular Psychiatry, 13, 953-969.
http://dx.doi.org/10.1038/sj.mp.4002077

has been cited by the following article:

• TITLE: Magnesium Therapy Prevents Senescence with the Reversal of Diabetes and Alzheimer’s Disease

  AUTHORS: Ian James Martins

  KEYWORDS: Magnesium, Cholesterol, Amyloid Beta, Infarct, Lipopolysaccharides

  JOURNAL NAME: Health, Vol.8 No.7, May 27, 2016

  ABSTRACT: In the current global epidemic for Non Alcoholic Fatty Liver Disease (NAFLD), diabetes and neuro-degenerative diseases such as Alzheimer’s disease there has been a major interest in magnesium therapy to delay the severity of NAFLD, Type 3 diabetes and neurodegeneration in the developing and developed world. The objective of magnesium therapy is to activate the anti-aging gene Sirtuin 1 (Sirt1) to prevent cardiovascular disease, NAFLD and diabetes. Reduced consumption of nutrients such as fatty acids, glucose, cholesterol and increased magnesium consumption is closely linked to reduced bacterial lipopolysaccharides (LPS) and activation of Sirt1 relevant to active nuclear and mitochondria interactions with the prevention of myocardial infarction and Type 3 diabetes. Magnesium deficiency and its effects on Sirt1 regulation have become important with magnesium deficiency associated with appetite dysregulation, senescence, glucose/nitric oxide dyshomeostasis, increased ceramide and toxic amyloid beta formation. Magnesium therapy activates the peripheral sink amyloid beta clearance pathway with the reversal of cell senescence associated with various chronic diseases such as cardiovascular disease, Type 3 diabetes and Alzheimer’s disease.